about
H1N1v at a seroepidemiological glance: is the nightmare over?Regional spread of HIV-1 M subtype B in middle-aged patients by random env-C2V4 region sequencingThe L76V mutation in HIV-1 protease is potentially associated with hypersusceptibility to protease inhibitors Atazanavir and Saquinavir: is there a clinical advantage?Is transmission of HIV-1 in non-viraemic serodiscordant couples possible?Severe acute respiratory syndrome (SARS)--paradigm of an emerging viral infection.HIV-1 genotyping: comparison of two commercially available assays.Association of saquinavir plasma concentrations with side effects but not with antiretroviral outcome in patients infected with protease inhibitor-susceptible human immunodeficiency virus type 1Decrease of atazanavir and lopinavir plasma concentrations in a boosted double human immunodeficiency virus protease inhibitor salvage regimenMolecular assays for monitoring HIV infection and antiretroviral therapy.Quadruple nucleoside therapy with zidovudine, lamivudine, abacavir and tenofovir in the treatment of HIV.Human immunodeficiency virus: 25 years of diagnostic and therapeutic strategies and their impact on hepatitis B and C virus.Description of two commercially available assays for genotyping of HIV-1.HIV-2EU: supporting standardized HIV-2 drug resistance interpretation in Europe.Predictive factors for response to a boosted dual HIV-protease inhibitor therapy with saquinavir and lopinavir in extensively pre-treated patients.Comparison of drug resistance scores for tipranavir in protease inhibitor-naive patients infected with HIV-1 B and non-B subtypes.Human immunodeficiency virus type-1 group M quasispecies evolution: diversity and divergence in patients co-infected with active tuberculosis.Ultrasensitive monitoring of HIV-1 viral load by a low-cost real-time reverse transcription-PCR assay with internal control for the 5' long terminal repeat domain.A family of insertion mutations between codons 67 and 70 of human immunodeficiency virus type 1 reverse transcriptase confer multinucleoside analog resistance.A novel human immunodeficiency virus type 1 reverse transcriptase mutational pattern confers phenotypic lamivudine resistance in the absence of mutation 184VHIV-1 replication in central nervous system increases over time on only protease inhibitor therapy.Correlation of phenotypic zidovudine resistance with mutational patterns in the reverse transcriptase of human immunodeficiency virus type 1: interpretation of established mutations and characterization of new polymorphisms at codons 208, 211, and 2Prevalence of K65R in patients treated with tenofovir disoproxil fumarate: recommendations based on the Frankfurt HIV Cohort Study Resistance Database (FHCS-RD).Novel approach for genotyping varicella-zoster virus strains from Germany.Maternal CD4+ microchimerism in HIV-exposed newborns after spontaneous vaginal delivery or caesarean section.Mutations in the C-terminal region of the HIV-1 reverse transcriptase and their correlation with drug resistance associated mutations and antiviral treatment.Lopinavir/ritonavir pharmacokinetics, efficacy, and safety in HIV and hepatitis B or C coinfected adults without symptoms of hepatic impairment.Detection and quantitation of HBV DNA in miniaturized samples: multi centre study to evaluate the performance of the COBAS ® AmpliPrep/COBAS ® TaqMan ® hepatitis B virus (HBV) test v2.0 by the use of plasma or serum specimens.Case report: risk of virus infection after accidental blood inoculation from a multi-infected AIDS patient.Intensification of a failing regimen with zidovudine may cause sustained virologic suppression in the presence of resensitising mutations including K65R.Impact of HIV-1 replication on immunological evolution during long-term dual-boosted protease inhibitor therapy.Laboratory diagnosis of influenza--virology or serology?Evaluation of the Cobas AmpliPrep/Cobas Amplicor HIV-1 Monitor Ultrasensitive Test: comparison with the Cobas Amplicor HIV-1 Monitor test (manual specimen preparation).Do fewer cases of Kaposi's sarcoma in HIV-infected patients reflect a decrease in HHV8 seroprevalence?Comparison of nine resistance interpretation systems for HIV-1 genotyping.A 6-base pair insertion in the protease gene of HIV type 1 detected in a protease inhibitor-naive patient is not associated with indinavir treatment failure.Haemolytic anaemia after nucleotide antiretroviral treatment discontinuation in a chronic hepatitis B-virus co-infected AIDS patient.Schnelltest-Diagnostik sexuell übertragbarer Infektionen in niedrigschwelligen Einrichtungen : Gemeinsame Stellungnahme des RKI, PEI und der DSTIG.Short communication: Different mutation patterns in subtype CRF06_cpx after mother-to-child transmission.Laboratory diagnosis of norovirus: which method is the best?The M184V mutation in HIV-1 reverse transcriptase (RT) conferring lamivudine resistance does not result in broad cross-resistance to nucleoside analogue RT inhibitors.
P50
Q30409115-0060C431-543C-4319-9033-C884557B83D1Q33788384-2C80A61E-72D6-4345-8925-40E774B11141Q34626108-916E3BDD-362D-4C13-9EDB-0FF45425809DQ34821169-3598D9B5-ACAF-4BB7-A8E5-860FEB8DF51DQ35607877-A5922D13-DC55-473A-9348-D91A581C629AQ35770546-05D786A6-8F43-4DE5-BAC6-FACDD2D6AD9DQ36094901-0A9372D3-E11C-4F5C-88A6-68CE2ADC529FQ36702983-5D6C22B8-433F-437A-B5DC-76F6F8BF953DQ36816024-AC52B6B8-027E-4EC3-9EEE-EEB146FBBD95Q36916387-ED3810B3-16DE-4A46-BA17-A437D863B8D9Q37271640-0FC62CC7-6A3E-46CA-83F1-900C28EC009FQ37979704-B15B6B4B-C76F-4B2C-85DD-DDE505475E21Q38083487-BDD85B5E-A26F-4944-A666-4B0A6CDEE87BQ38427935-D76F8BF9-DBEF-450F-9E22-6FE806F6A28EQ38726300-36A38BBD-1312-462D-97F3-17F9D48D2E8CQ38909973-1BD121D0-5358-4AC4-979D-C9BAE79F7535Q38978220-88FB5CA2-97DD-4AF2-95FA-99C1CBEC2A09Q39471491-3664B4F6-0AAC-4A11-AAC8-BD30B75E20B4Q39473036-AE198FE4-1AE0-4BE2-93D4-F30F6242B2A6Q39548875-AC986D08-A8B7-4839-A1ED-AC118DC5E007Q39730755-67EDA77C-C8F0-4AED-A0CE-A4A368D1D330Q40128143-968FDFA6-F660-49A1-A88E-1E67C1F07FA9Q40174164-ACB05DF6-E72C-4E78-B0AA-73EC02804010Q40634046-8EFED3D8-2EAD-499D-BF59-305965944E76Q42164431-E927789C-047E-4486-B4D6-20837375DD4BQ42231192-713E8F2C-054D-44F3-A386-16F10AC3B2F8Q42930444-D5A5B334-5F44-4C1C-8B14-6A5E94855245Q42979319-7EC68C1F-D6DB-4783-B9A9-30CB2CD15E13Q42988696-7B445377-9804-4611-8DE6-77E4024E5D3CQ43760953-E6CAB33D-B6F1-46DE-8A2D-22B2DE8A781FQ43849964-B70136C1-526F-4672-AA2A-3ECD3A4AC47DQ44239710-57163016-2518-4B98-8D61-8CBC271BD434Q44417541-6669BAB5-3254-4F51-AA18-61335A1AA7DBQ44552923-F864FD63-9961-4225-9646-6E2C49368BC2Q44695492-888EC405-1CEE-445D-98B4-8070F80AB918Q44967524-BE04ABE3-AF0B-4AF5-9195-CB5B2702C9C1Q45030352-99B37E43-60F7-4D9F-9098-D6D071540539Q46229848-14F93EBA-2F5E-4D12-92FD-BF33D6BFF7A8Q47674093-BBDE9843-0546-4051-B34E-009B3D0EB69DQ47995405-14227AB7-877F-4C28-B6EC-4E664242FB32
P50
description
Duits onderzoeker
@nl
German virologist
@en
German virologist
@en-ca
German virologist
@en-gb
deutscher Virologe
@de
virólogo alemán
@es
հետազոտող
@hy
عالم فيروسات ألماني
@ar
name
Martin Stürmer
@ast
Martin Stürmer
@de
Martin Stürmer
@en
Martin Stürmer
@es
Martin Stürmer
@nl
Martin Stürmer
@sl
type
label
Martin Stürmer
@ast
Martin Stürmer
@de
Martin Stürmer
@en
Martin Stürmer
@es
Martin Stürmer
@nl
Martin Stürmer
@sl
prefLabel
Martin Stürmer
@ast
Martin Stürmer
@de
Martin Stürmer
@en
Martin Stürmer
@es
Martin Stürmer
@nl
Martin Stürmer
@sl
P106
P21
P31
P496
0000-0003-4300-9315
P6634
martin-stuermer-08539394